Please assess the completion status of the following clinical trial:

Trial Title: Gemcitabine Plus Carboplatin Versus Carboplatin Monotherapy in Patients With Advanced Ovarian Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Histologically proven ovarian cancer with evidence of recurrence or progression~* Failed first-line platinum containing therapy after 6 months of treatment discontinuation~* Documented lesion as evidenced by appropriate computerized tomography (CT), magnetic resonance imaging (MRI) scan, chest x-ray, or ultrasound.~* Previous hormonal therapy or radiotherapy must be terminated at least 3 weeks before study drug administration~* Adequate bone marrow reserve: neutrophils ≥ 1.5 x 10\^9/L and platelets ≥ 100 x 10\^9/L~Exclusion Criteria:~* Receiving concomitant cytotoxic or other antineoplastic treatment. Hormone replacement therapy is allowed, as are steroid antiemetics~* Clinical evidence of central nervous system metastases~* Active infection~* Cannot adequately be followed up for the duration of the study~* A second primary malignancy (except in situ carcinoma of the cervix or adequately treated basal cell carcinoma of the skin)~* Use of any investigational agent in the 3 weeks prior to inclusion~* Serious concomitant systematic disorders incompatible with the study~* Received more than one previous chemotherapy regimen or had prior gemcitabine treatment~* Patients with tumor of borderline malignancy~* Patients with estimated GFR ≤ 50 mL/min

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).